Posted on May 20, 2020 by Sitemaster
Following last week’s approval of rucaparib (Rubraca), the US Food and Drug Administration (FDA) has now, also, approved the PARP inhibitor olaparib (Lynparza) for the treatment of men with with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, inhibitor, Lynparza, mCRPC, metastatic, olaparib, PARP | 1 Comment »
Posted on April 27, 2020 by Sitemaster
According to a media release issued by AstraZeneca and Merck on Friday evening, olaparib (Lynparza) has shown “a statistically significant and clinically meaningful improvement in … overall survival (OS)” in men with metastatic, castration-resistant prostate cancer (mCRPC) and BRCA1/2 or ATM gene mutations (homologous repair gene mutations or HRRm). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: gene, Lynparza, mCRPC, mutation, olaparib, Profound, repair | 11 Comments »
Posted on October 1, 2019 by Sitemaster
From a report presented by Hussain yesterday at the annual meeting of the European Society for Medical Oncology (ESMO) we gained detailed insight into the results of the PROfound trial of olaparib (Lynparza), which had been said to be positive last August. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, gene, Lynparza, mCRPC, metastatic, mutation, olaparib | 3 Comments »
Posted on October 28, 2015 by Sitemaster
A paper in the New England Journal of Medicine now provides detailed information about the activity of the PARP inhibitor olaparib in the treatment of carefully selected patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, inhibitor, Lynparza, mCRPC, metastatic, olaparib, PARP | 3 Comments »
Posted on April 21, 2015 by Sitemaster
According to a presentation at the ongoing annual meeting of the American Association for Cancer Research (AACR) meeting here in Philadelphia, AstraZeneca’s PARP inhibiting agent — olaparib or Lynparza — continues to show promise in very late stage metastatic, castration-resistant prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: inhibitor, Lynparza, olaparib, PARP | 4 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 